 |
The European Medicines Agency has released a statement indicating that one of its advisory committees will launch a review of the risks and benefits of Tysabri in light of 23 confirmed cases of progressive multifocal leukoencephalopathy (PML) that it says have occurred since the drug has been on the market.
To read more, as reported by the US National MS Society, click here.
Source: US National MS Society
|
